Welcome!

News Feed Item

Small-Molecule Targeted Cancer Therapies: World Market 2013-2023

NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Small-Molecule Targeted Cancer Therapies: World Market 2013-2023

http://www.reportlinker.com/p0733756/Small-Molecule-Targeted-Cancer-Ther...

Report Details

Cancer treatment with small molecules - your guide to trends and revenue prospects

You see the potential of those molecularly-targeted technologies and products. Our new analysis lets you assess forecasted sales at overall world market, product and national level. Discover how and why revenues can increase.

Forecasts and other analyses to help you find the best growth opportunities

In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You gain 72 tables, 34 charts and four research interviews.

You can stay ahead in knowledge, benefiting your research and analyses. Much scope remains for medicines to combat growth, progression and spread of tumours (tumors). Our work lets you investigate the most promising areas of that drug industry and market.

The following sections show what you discover in our report.

You see prospects for the world market and top products

Along with predictions of overall world market value, you see revenue forecasts for 10 leading brands at world level. You find data from 2011 to 2023 for these products: • Glivec (Gleevec)• Revlimid• Alimta• Velcade• Tarceva• Taxotere• Sutent• Nexavar• Sprycel• Arimidex.

You find analysis of competition, as well as commercial drivers and restraints. Discover the potential of those targeted applications of oncology.

Our work also breaks the overall world forecast into prominent national markets.

What are the prospects in leading countries?

There are many opportunities in developed and developing countries, our report explains.

You discover individual revenue forecasts to 2023 for nine national markets, seeing relevant overall sales:

• US

Japan

Germany, France, UK, Italy and Spain (EU5)

India and China.

See what's likely to happen. There will be strong growth in established markets and in developing countries, our analyses show. You find areas with highest potential.

China and India, in particular, will achieve high revenue growth. Other markets - including the US - will also expand fast. Launch of new products will stimulate growth worldwide.

What about the oncology R&D pipeline for those drugs?

• Kinase inhibitors and signal transduction blockers

• VEGF agents and androgen receptor antagonism

• Signal transduction blocking and proteasome inhibition candidates

• Immunomodulators, aurora kinase inhibiting and peptide prodrugs

• Gene expression, epigenetic treatments and cellular function regulators

• E-selectin antagonists and histone deacetylase inhibitors.

Our work also discusses these technologies and others, including pharmacogenomics:• Mitosis inhibitors and apoptosis inducers• HDAC mechanisms and other drug targets• Heat shock protein (HSP) modulators• Hormones and angiogenesis blockers• Transcription factor regulators and siRNA processes and products• Biomarkers, genome screening and molecular diagnostics (inc. theranostics).

R&D pipelines for targeted therapies are vast and strong. Discover progress for injectable and oral medicines, including antineoplastics. Also, you see outlooks for treating solid tumours and other forms. You gain insight into developments and their significance.

Emerging technology holds great promise. Many opportunities exist for large companies and specialty pharma firms, allowing market expansion from 2013.

Leading companies and market value in 2016

Overall world revenue for that market area will reach $32.7bn in 2016, our report forecasts. We predict strong revenue growth to 2023, owing to rising demand for anti-cancer medicines. Rising disease incidence and prevalence will stimulate market growth.

In our study you find discussions of Novartis, Eli Lilly, Roche, Pfizer, Takeda and many other developers and manufacturers. You find outlooks for revenue growth.

This decade, many opportunities will arise for pharmaceutical and biotechnology companies in targeted cancer treatment. Our work shows you the commercial possibilities.

Nine ways Small-Molecule Targeted Cancer Therapies: World Market 2013-2023 helps you

To sum up, our investigation gives you the following knowledge on the topic:• Forecasted revenues to 2023 for the overall world market - you discover the industry's future prospects• Predicted revenues of 10 leading products to 2023 - you analyse crucial developments for top brands• Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, India and China - you see national sales outlooks• Review of R&D pipelines by treatment area and technology - you hear about progress in established and emerging research areas• Assessment of companies - you find activities, products, strategies and outlooks• Opinions on the sector - you discover our interviews with authorities in the field• Competition and opportunities influencing sales - you see what affects the future• Discussions of what stimulates and restrains the industry and market - you assess business trends, drivers and restraints• Prospects for established firms and specialists seeking to enter the sector - you see factors and outlooks for success.

You gain information found nowhere else

That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative.

With our report you are less likely to fall behind in knowledge or miss opportunity. Discover how our work could benefit your research, analyses and decisions, saving you time and getting you recognition for commercial insight.

Ordering now lets you discover prospects to 2023 for small-molecule anti-cancer drugs

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents

1. Executive Summary1.1 Overview of Findings 1.2 Scope and Format of the Report1.3 Research and Analysis Methods

2. Introduction: Cancer, its Physiology, Burden and Treatment

2.1 Targeted Cancer Therapies

2.2 The Physiology of Cancer

2.2.1 Uncontrolled Growth

2.2.2 Dedifferentiation

2.2.3 Invasiveness and Metastasis

2.2.4 Causes of Cancer

2.3 Incidence and Mortality for Cancer

2.3.1 Incidence

2.3.2 Mortality

2.3.3 Survival

2.3.3.1 The Developed World

2.3.3.2 The Developing World

2.4 Treating Tumours

2.4.1 Chemotherapy

2.4.2 Traditional Antineoplastics

2.4.3 Novel Antineoplastics

2.4.3.1 Kinase Receptor Antagonists

2.4.3.2 Other Novel Antineoplastics

2.4.4 Hormone Therapies

2.4.5 Active Immunotherapy

2.4.6 Passive Immunotherapy: Monoclonal Antibodies

2.5 Small-Molecule Targeted Cancer Therapies

2.5.1 Signal Transduction Inhibitors

2.5.2 Gene Expression and Other Cellular Function Regulators

2.5.3 Small-Molecule Apoptotic Inducing Drugs

2.5.4 Angiogenesis Blockers

2.6 Targeted Cancer Therapies: Small-Molecule Drugs

3. The Small-Molecule Cancer Therapies Market, 2013-20233.1 The World Small-Molecule Cancer Therapies Market in 2011 3.2 Growing Market for Small-Molecule Cancer Therapies3.2.1 Sales Forecast for Small-Molecule Cancer Therapies, 2012-20163.2.2 Sales Forecast for Small-Molecule Cancer Therapies, 2017-20233.3 Leading Products in the Small-Molecule Cancer Therapies Market

4. Small-Molecule Cancer Therapies: Leading National Markets, 2013-2023

4.1 The US Small-Molecule Cancer Therapies Market, 2012-2023

4.2 The Japanese Small-Molecule Cancer Therapies Market, 2012-2023

4.3 The Leading European Small-Molecule Cancer Therapies Markets, 2012-2023

4.4 Emerging-Economy Small-Molecule Cancer Therapies Markets

4.5 The Chinese Small-Molecule Cancer Therapies Market, 2012-2023

4.6 The Indian Small-Molecule Cancer Therapies Market, 2012-2023

4.7 Summary of Market Forecasts

5. Leading Small-Molecule Anti-Cancer Products, 2013-20235.1 Glivec/Gleevec (Novartis)5.1.1 Glivec/Gleevec Sales 20115.1.2 Glivec/Gleevec Sales Forecast, 2012-20165.1.3 Glivec/Gleevec Sales Forecast, 2017-20235.1.4 Tasigna Set to Replace Glivec/Gleevec5.2 Revlimid (Celgene)5.2.1 Revlimid Sales 20115.2.2 Secondary Malignancies5.2.3 Revlimid Sales Forecast, 2012-20165.2.4 Revlimid Sales Forecast, 2017-20235.3 Alimta (Eli Lilly)5.3.1 Alimta Sales 20115.3.2 Patent Disputes5.3.3 Alimta Sales Forecast, 2012-20165.3.4 Alimta Sales Forecast, 2017-20235.4 Velcade (Takeda/J&J)5.4.1 Velcade Sales 20115.4.2 Recent Developments5.4.3 Velcade Sales Forecast, 2012-20165.4.4 Velcade Sales Forecast, 2017-20235.5 Tarceva (Roche)5.5.1 Tarceva Sales 20115.5.2 Patent Expiry5.5.3 Tarceva Sales Forecast, 2012-20165.5.4 Tarceva Sales Forecast, 2017-20235.6 Taxotere (Sanofi)5.6.1 Taxotere Sales 20115.6.2 Patent Expiry5.6.3 Taxotere Sales Forecast, 2012-20165.6.4 Taxotere Sales Forecast, 2017-20235.7 Sutent (Pfizer)5.7.1 Sutent Sales 20115.7.2 Generics Challenges5.7.3 Sutent Sales Forecast, 2012-20165.7.4 Sutent Sales Forecast, 2017-20235.7.5 Additional Indication Approval.5.7.6 Late-Stage Clinical Trials for Additional Uses and Dosage Forms for Sutent5.8 Nexavar (Bayer/Onyx)5.8.1 Nexavar Sales 20115.8.2 Patent Expiry 5.8.3 Nexavar Sales Forecast, 2012-20165.8.4 Nexavar Sales Forecast, 2017-20235.9 Sprycel (Bristol-Myers Squibb)5.9.1 Sprycel Sales 20115.9.2 Patent Expiry 5.9.3 Sprycel Sales Forecast, 2012-20165.9.4 Sprycel Sales Forecast, 2017-20235.10 Arimidex (AstraZeneca)5.10.1 Arimidex Sales 20115.10.2 Patent Expiry5.10.3 Arimidex Sales Forecast, 2012-20165.10.4 Arimidex Sales Forecast, 2017-2023

6. R&D Pipeline for Small-Molecule Cancer Products

6.1 Overview

6.2 Small-Molecule Lung Cancer Pipeline 2012

6.2.1 Afatinib (Boehringer Ingelheim), a Second-generation Tyrosine Kinase Inhibitor

6.2.2 Crizotinib/Xalkori (Pfizer) Receives FDA Approval

6.3 Small-Molecule Breast Cancer Pipeline 2012

6.3.1 Line Extensions

6.3.2 Halaven (Eisai) Enters Phase III for Non-Small Cell Lung cancer

6.4 Small-Molecule Colorectal Cancer Pipeline 2012

6.4.1 Regorafenib/BAY73-4506 (Bayer), a Promising Candidate Targeting Multiple Pathways including VEGF

6.4.2 Perifosine/KRX 0401 (Keryx/Aeterna Zentaris), Oral P13K Inhibitor Granted Fast Track Status by FDA

6.5 Small-Molecule Stomach Cancer Pipeline 2012

6.5.1 Line Extensions

6.5.2 Telatinib, ACT Biotech's Lead Anti-angiogenic Pipeline Product

6.6 Small-Molecule Prostate Cancer Pipeline 2012

6.6.1 MDV 3100 (Astellas/Medivation), an Oral Androgen Receptor Antagonist

6.6.2 CB7630 (Centocor Ortho Biotech) Formulated as a Prodrug for Prostrate Cancer

6.7. Small-Molecule Multiple Myeloma Pipeline, 2012

6.7.1 Proteasome Inhibitors: the Next Generation

6.7.1.1 CEP 18770 (Cephalon) - Late-phase Trials for Relapsed/Refractory Multiple Myeloma

6.7.1.2 Marizomib (Nereus) Shows Promising Results in Early-phase Trials

6.7.1.3 MLN 9708 (Takeda), First Oral Proteosome Inhibitor to Reach Clinical Trials

6.7.1.4 CEP 28331 (Cephalon), Another Proteosome Inhibitor in Development

6.7.2 Immunomodulators: The Past or the Future for Myeloma Treatment?

6.7.2.1 Afinitor (Novartis) Shows Positive Data for Myeloma in Early-stage Trials

6.7.2.2 E-Selectin Antagonists (GlycoMimetics)

6.7.3 Histone Deacetylase Inhibitors: An Important Field

6.7.3.1 Istodax (Celgene Corporation) in Late-phase Trials for Myeloma and T-cell Lymphoma

6.7.3.2 Zolinza (Merck & Co.) in Late-phase Development for Mesothelioma and Other Indications

6.7.3.3 AR 42 (Arno), a Histone Deacetylase Inhibitor Showing Early Promise

6.7.3.4 Givinostat (Italfarmaco) in Trials for Relapsed/Refractory Multiple Myeloma Patients

6.7.3.5 HDAC6 Inhibitors (Acetylon) Targeting Multiple Myeloma

6.7.4 Kinase Inhibitors/Signal Transduction Blockers: The Largest Pipeline Sector

6.7.4.1 Votrient (GlaxoSmithKline): Late-phase Development for Ovarian, Breast and Soft Tissue Sarcoma

6.7.4.2 Lenocta (VioQuest), a Promising Tyrosine Phosphatise Inhibitor

6.7.4.3 Ruxolitnib (Novartis) in Late-phase Trials for Multiple Indications

6.7.4.4 Lestaurtnib (Cephalon), a Tyrosine Kinase Inhibitor Reaches Phase III for Myeloma and Prostrate Cancer

6.7.4.5 Masitnib (AB Science) in Late-phase Trials for a Range of Cancer Indications

6.7.4.6 AT 9283 (Astex Therapeutics), a JAK-2 & Mitosis Inhibitor in Multiple Trials

6.7.4.7 Dovitnib (Novartis) Begins Phase II Testing for Myeloma and Other Indications

6.7.4.8 P276 (Piramal Life Sciences) CDK1/4 Inhibitor Targeting Multiple Indications

6.7.4.9 PD332991 (Pfizer) Enters Late-phase Development for Multiple Indications

6.7.4.10 ENMD 2076 (EntreMed) Receives Orphan Drug Status in the US

6.7.4.11 AT 7519 (Astex Therapeutics), an Injectable CDK Inhibitor with Promise in Mono and Combination Therapy

6.7.4.12 MLN 8237 (Takeda), a Promising Oral Bioavailable Drug in Trials for Multiple Indications

6.7.4.13 Estybon (Onconova) in Development for Multiple Cancer Indications

6.7.4.14 CX 4945 (Cylene), a CK2 Inhibitor in Early Development

6.7.4.15 GDC 0941 (Roche), a Promising Candidate in Early-phase Trials for Multiple Indications

6.7.4.16 INK 128 (Intellikine): Targeting TORC1/2 Pathway

6.7.4.17 SF 1126 (Semafore), an Injectable Peptide Prodrug Targeting PI 3-Kinase Pathway

6.7.4.18 SNS 032 (Sunesis/Bristol-Myers Squibb) in Early Development for Multiple Indications

6.7.4.19 Sprycel (Otsuka/Bristol-Myers Squibb): Abl/Src Tyrosine Tinase Inhibitor in Multiple Trials

6.7.4.20 TG 02 (Tragara/S*BIO) in Trials for Relapsed/Refractory Myeloma

6.7.4.21 R763 (Rigel), an Aurora Kinase Inhibitor with Anti-Myeloma Promise

6.7.5 Heat Shock Protein (HSP) Modulators

6.7.5.1 AUY 922 (Novartis) in Early Trials for Solid Tumour and Myeloma

6.7.5.2 KW 2478 (Kyowa Hakko Kirin), a HSP90 Inhibitor intended for Non-Hodgkin's Lymphoma and Other Indications

6.7.5.3 NVP BEP800 (Novartis): HSP90 Inhibitor with Early Promise

6.7.6 Apoptosis Inducers: Four Products at Phase II

6.7.6.1 GCS 100 (Prospect Therapeutics) in Late-stage Development for Multiple Indications

6.7.6.2 Amplimexon (AmpliMed) - US Orphan Drug Designation for Several Indications

6.7.6.3 Trisenox (Nippon Shinyaku), a Promising Apoptotic with Unknown Mechanism

6.7.6.4 Noscapine (Cougar Biotechnology), an Orally Active Alkaloid Showing Early Promise

6.7.6.5 BMS 833923 (Bristol-Myers Squibb): Targets Hedgehog Pathway

6.7.6.6 SNS 01-T (Senesco): siRNA Product Designated US Orphan Drug Status

6.7.7 Other Small-Molecule Myeloma Products

6.7.7.1 Products in Phase II

6.7.7.2 Amnolake (CytRx) in Late-stage Development for Multiple Indications

6.7.7.3 Coprexa TM (Attenuon) in Phase II Trials

6.7.7.4 Brostallacin (Cell Therapeutics), a Potential Chemotherapy Agent

6.7.7.5 CYT 997 (YM BioSciences) in Late-phase Development in Australia

6.7.7.6 ARRY 520 (Array BioPharma), a Promising Injectable for AML and Myeloma

6.7.7.7 Zinapar (Ziopharm) in Development for Multiple Indications

6.7.7.8 Products in Phase I

6.7.7.9 Quadramet (EUSA Pharma) in Late-stage Trials for Metastasis and Prostate Cancer

6.7.7.10 LC1 (Leuchemix): Orally-bioavailable Parthenolide Analogue

6.7.7.11 MLN 4924 (Takeda): Targets Multiple Oncology Indications

6.7.7.12 OPB 31121 (Otsuka), a Transcription Factor Regulator/STAT Inhibitor in Early-Phase Development

6.7.7.13 Zalypsis (PharmaMar), an Injectable Candidate for Lymphoma and Solid Tumours

6.7.7.14 Products in Preclinical Studies

6.7.7.15 INNO 206 (CytRx), Showing Early Promise in Myeloma

6.7.7.16 Ostabolin-C (Zelos), a Parathyroid Hormone Analogue with Potential in Myeloma Treatment

6.7.7.17 IRE1-alfa inhibitor (Mannkind), First-in-class Candidate Targeting Novel Pathways

6.7.7.18 HIF Signalling Inhibitors (Elara)

6.7.7.19 PS 031291 (Ligand), Promising Chemokine Receptor 1 (CCR1) Antagonist

6.7.7.20 SST 0001 (Sigma-Tau), Aimed at bFGF Growth Factors

6.7.7.21 CGEN 928 (Compugen), Targeting Multiple Myeloma

6.7.7.22 Ubiquitin-Specific Peptidase 7 (USP7) Inhibitors by Progenra

6.8 Small-Molecule Epigenetic Therapy Pipeline, 2012

6.8.1 HDAC Inhibitors

6.8.1.1 PXD-101 (Belinostat, TopoTarget/Spectrum Pharmaceuticals)

6.8.1.2 LBH589 (Panobinostat, Novartis), Gains Orphan Drug Status for Hodgkin's Lymphoma

6.8.1.3 Entinostat (Syndax Pharmaceuticals), Targeting Breast and Lung Indications

6.8.1.4 4SC-201 (Resminostat, 4SC), Oral Pan-HDAC Inhibitor in Development for Variety of Cancers

6.8.1.5 MGCD-0103 (Mocetinostat, MethylGene), Targeting Class I/IV Histone Deacetylases

6.8.1.6 SB939 (S*BIO), First Anti-cancer Therapy Developed in Singapore

6.8.1.7 ACY-1215, Acetylon Pharmaceuticals' Second Generation HDAC Inhibitor for Multiple Myeloma

6.8.1.8 Valproic Acid, an Epilepsy Drug in Multiple Trials for Cancer Indications

6.8.2 DNMT Inhibitors

6.8.2.1 SGI-110, Astex Pharmaceuticals' Second Generation DNMT Inhibitor

6.8.2.2 CP-4200 (Clavis Pharma) - Showing Early-stage Promise

7. Qualitative Analysis of the Small-Molecule Cancer Therapies Market, 2013-20237.1 SWOT Chart for Small-Molecule Cancer Therapies Market 2013-20237.2 Strengths7.2.1 Cancer Treatment has Proven Commercial Potential7.2.2 High Profile Nature of Cancer7.2.3 Off-Label Prescriptions are Common7.2.4 Strong Drug Development Incentives7.3 Weaknesses7.3.1 Tumours and Multidrug Resistance (MDR) 7.3.2 Pricing-Out the Developing World?7.4 Opportunities7.4.1 Cancer is a Key Business Area for the Pharmaceutical Industry7.4.2 Rising Incidence of Cancer7.4.1.1 Aging Populations7.4.1.2 Smoking7.4.1.3 Obesity7.4.1.4 The Developing World7.4.3 Greater Understanding of Cancer Gives Opportunities in the Cancer Treatment Industry7.4.4 Advanced Diagnostics with Pharmacogenomics: Impact on Cancer Therapies7.4.5 Live Licensing and In-Life Testing7.4.6 Convenience of Targeted Drugs versus Chemotherapy7.5 Threats7.5.1 Healthcare Spending Restraints Threaten Cancer Drug Revenues7.5.2 The Cost-Effectiveness Debate7.5.3 Governments are a Leading Payer for Drugs7.5.4 Efficacy, Toxicity and Alternative Treatments7.6 Biosimilars and Generics: Opportunity or Threat?7.7 Personalised Medicine and Cancer7.7.1 Biomarkers and Diagnostics7.7.2 Small-Molecule (Metabolic) Biomarkers7.7.3 Cancer Heterogeneity7.7.4 Pharmacogenomics7.7.5 Genome Screening7.7.6 Theranostics

8. Research Interviews

8.1 Dr Martin Bonde, CEO, EpiTherapeutics

8.1.1 Potential for Histone Methyltransferase Inhibitors

8.1.2 Future of Epigenetics Research

8.1.3 Histone Methyltransferase Inhibitors on Market within Decade?

8.1.4 Challenges in Developing Epigenetic Therapies

8.1.5 Benefits of University Spin-Outs

8.2 Dr Joanna Horobin, President and CEO, Syndax Pharmaceuticals

8.2.1 On Challenges Facing Cancer Therapies

8.2.2 On Selective Targeting of Therapies

8.2.3 On Drug Resistance and Targeted Therapies

8.2.4 On Drug Resistance and Market Opportunity

8.2.5 On Entinostat, Lung and Breast Cancer Therapies

8.3 Interview with an External Authority (Views Given Anonymously)

8.3.1 Obesity is a Strong Risk Factor for Cancer

8.3.2 Multiple Myeloma Treatment: Proactive versus Reactive

8.3.3 Treatment Options for Obese Patients

8.3.4 Multiple Myeloma Incidence Will Increase Due To Obesity

8.4 Interview with Dr Kent C. Osborne, Baylor College of Medicine

8.4.1 On Challenges in Developing Anti-Cancer Therapies

8.4.2 On Major Areas of Focus

8.4.3 On Cancer Vaccines

8.4.4 On Areas with Potential for Increased Revenue Generation

8.4.5 On R&D Pipeline

8.4.6 On Difficulties Conducting Clinical Trials

9. Conclusions9.1 Small-Molecule Cancer Therapies Market Offers Promise9.2 Leading Products in Small-Molecule Cancer Therapies Market9.3 The US Will Remain the World's Largest Small-Molecule Cancer Therapies Market9.4 India and China Will be the Fastest-Growing National Markets9.5 R&D Pipelines for Many Cancer Types Are Strong9.6 Concluding Remarks

List of Tables

Table 2.1 Leading Causes of Death Worldwide, 2008 & 2015

Table 2.2 Most-Common Cancers by Incidence, 2008

Table 2.3 Most-Common Cancers by Mortality, 2008 & 2015

Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK, 2009

Table 2.5 Categories of Anti-Cancer Drug, 2012

Table 2.6 Common Side-effects of Traditional Antineoplastic Chemotherapy

Table 2.7 Subcategories of TANs, 2012

Table 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2011-2016

Table 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2017-2023

Table 3.3 Small-Molecule Cancer Market: Top Ten Products - Sales and Market Shares, 2011, 2016 & 2023

Table 4.1 Leading Small-Molecule Cancer Therapies: National Market Forecasts, 2011-2023

Table 5.1 Glivec/Gleevec Sales for US and RoW, 2009-2011

Table 5.2 Glivec/Gleevec Sales Forecast, 2011-2016

Table 5.3 Glivec/Gleevec Sales Forecast, 2017-2023

Table 5.4 Glivec/Gleevec: Sales Drivers and Restraints, 2012-2023

Table 5.5 Revlimid Sales Forecast, 2011-2016

Table 5.6 Revlimid Sales Forecast, 2017-2023

Table 5.7 Revlimid: Sales Drivers and Restraints, 2012-2023

Table 5.8 Alimta Sales for US and RoW, 2009-2011

Table 5.9 Alimta Sales Forecast, 2011-2016

Table 5.10 Alimta Sales Forecast, 2017-2023

Table 5.11 Alimta: Sales Drivers and Restraints, 2012-2023

Table 5.12 Velcade Sales by Company, 2009-2011

Table 5.13 Velcade Sales Forecast, 2011-2016

Table 5.14 Velcade Sales Forecast, 2017-2023

Table 5.15 Velcade: Sales Drivers and Restraints, 2012-2023

Table 5.16 Tarceva Sales Forecast, 2011-2016

Table 5.17 Tarceva Sales Forecast, 2017-2023

Table 5.18 Tarceva: Sales Drivers and Restraints, 2012-2023

Table 5.19 Taxotere: Approved Indications, 2012

Table 5.20 Taxotere Sales by Region, 2009-2011

Table 5.21 Taxotere Sales Forecast, 2011-2016

Table 5.22 Taxotere Sales Forecast, 2017-2023

Table 5.23 Taxotere: Sales Drivers and Restraints, 2012-2023

Table 5.24 Sutent Sales Forecast, 2011-2016

Table 5.25 Sutent Sales Forecast, 2017-2023

Table 5.26 Sutent: Sales Drivers and Restraints, 2012-2023

Table 5.27 Nexavar Sales Forecast, 2011-2016

Table 5.28 Nexavar Sales Forecast, 2017-2023

Table 5.29 Nexavar: Sales Drivers and Restraints, 2012-2023

Table 5.30 Sprycel Sales for US and RoW, 2009-2011

Table 5.31 Sprycel Sales Forecast, 2011-2016

Table 5.32 Sprycel Sales Forecast, 2017-2023

Table 5.33 Sprycel: Sales Drivers and Restraints, 2012-2023

Table 5.34 Arimidex Sales for US and RoW, 2009-2011

Table 5.35 Arimidex Sales Forecast, 2011-2016

Table 5.36 Arimidex Sales Forecast, 2017-2023

Table 5.37 Arimidex: Sales Drivers and Restraints, 2012-2023

Table 6.1 Abbreviations Used in Chapter 6

Table 6.2 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase III, 2012

Table 6.3 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase II/III, 2012

Table 6.4 Selected Small-Molecule Breast Cancer Pipeline Candidates in Phase II & III, 2012

Table 6.5 Selected Small-Molecule Colorectal Cancer Pipeline Candidates in Phase II & III, 2012

Table 6.6 Selected Small-Molecule Stomach Cancer Pipeline Candidates in Phase II & III, 2012

Table 6.7 Selected Small-Molecule Prostate Cancer Pipeline Candidates in Phase II & III, 2012

Table 6.8 Small-Molecule Pipeline Products for Multiple Myeloma, 2012

Table 6.9 Small-Molecule Multiple Myeloma Pipeline: Proteasome Inhibitors, 2012

Table 6.10 Small-Molecule Multiple Myeloma Pipeline: Immunomodulators, 2012

Table 6.11 Small-Molecule Multiple Myeloma Pipeline: Histone Deacetylase Inhibitors, 2012

Table 6.12 Small-Molecule Multiple Myeloma Pipeline: Kinase Inhibitor/Signal Transduction Blockers, 2012

Table 6.13 Small-Molecule Multiple Myeloma Pipeline: Heat Shock Protein Modulators, 2012

Table 6.14 Small-Molecule Multiple Myeloma Pipeline: Apoptosis Inducers, 2012

Table 6.15 Other Small-Molecule Myeloma Products: Phase II Pipeline, 2012

Table 6.16 Other Small-Molecule Myeloma Products: Phase I Pipeline, 2012

Table 6.17 Other Small-Molecule Myeloma Products: Preclinical Pipeline, 2012

Table 6.18 Selected Small-Molecule HDAC Inhibitor Pipeline Candidates, 2012

Table 6.19 Ongoing Clinical Trials for PXD-101 (Belinostat), 2012

Table 7.1 STEP Analysis of World Small-Molecule Cancer Drugs Market, 2013-2023

Table 7.2 SWOT Analysis of World Small-Molecule Cancer Drugs Market: Strengths and Weaknesses, 2013-2023

Table 7.3 SWOT Analysis of World Small-Molecule Cancer Drugs Market: Opportunities and Threats, 2013-2023

Table 9.1 Small-Molecule Cancer Drug Market: Top Ten Products - Sales and Market Shares, 2011

Table 9.2 Small-Molecule Cancer Drugs Market by Country, 2011, 2016, 2020 & 2023

List of Figures

Figure 2.1 Leading Causes of Death Worldwide, 2008 & 2015Figure 2.2 Most-Common Cancers by Incidence, 2008Figure 2.3 Most-Common Cancers by Mortality, 2008Figure 2.4 Most-Common Cancers by Mortality, 2015Figure 2.5 Five-Year Survival Rates of Nine Cancers in the UK, 2009Figure 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2011-2016Figure 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2017-2023Figure 3.3 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2011Figure 3.4 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2016Figure 3.5 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2020Figure 3.6 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2023Figure 4.1 Leading National Small-Molecule Cancer Therapies Market Forecasts, 2011-2023Figure 4.2 National Small-Molecule Cancer Therapies Market Forecasts: Lower Range, 2011-2023Figure 4.3 Small-Molecule Cancer Therapies: Leading National Markets, 2011Figure 4.4 Small-Molecule Cancer Therapies: Leading National Markets, 2016Figure 4.5 Small-Molecule Cancer Therapies: Leading National Markets, 2020Figure 4.6 Small-Molecule Cancer Therapies: Leading National Markets, 2023Figure 5.1 Glivec/Gleevec Sales for US and RoW, 2011Figure 5.2 Glivec/Gleevec Sales Forecast, 2011-2023Figure 5.3 Revlimid Sales Forecast, 2011-2023Figure 5.4 Alimta Sales for US and RoW, 2011Figure 5.5 Alimta Sales Forecast, 2011-2023Figure 5.6 Velcade Sales by Company, 2011Figure 5.7 Velcade Sales Forecast, 2011-2023Figure 5.8 Tarceva Sales Forecast, 2011-2023Figure 5.9 Taxotere Sales by Region, 2011Figure 5.10 Taxotere Sales Forecast, 2011-2023Figure 5.11 Sutent Sales Forecast, 2011-2023Figure 5.12 Nexavar Sales Forecast, 2011-2023Figure 5.13 Sprycel Sales for US and RoW, 2011Figure 5.14 Sprycel Sales Forecast, 2011-2023Figure 5.15 Arimidex Sales by Region, 2011Figure 5.16 Arimidex Sales Forecast, 2011-2023Figure 9.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2011, 2013, 2016, 2020 & 2023

Companies Listed

4SC

AB Science

Abbott Laboratories

Abgenix

Abraxis BioScience

Acceleron

Acetylon Pharmaceuticals

ACT Biotech

Actavis

Active Biotech

Adeona (formerly Pipex)

AERES Biomedical

Aeterna Zentaris

Agennix

Alexion

Alza

Allos Therapeutics

Ambit Biosciences

American Society of Clinical Oncology (ASCO)

American Society of Hematology (ASH)

Amgen

AmpliMed

Anthrogenesis

Apexigen

Apotex

APP Pharmaceuticals (part of the Fresenius Kabi Group)

ARIAD Pharmaceuticals

Arizona University

Arno

ArQule

Array BioPharma

Ascenta Therapeutics

Astellas Pharma

Astex Pharmaceuticals

Astex Therapeutics

AstraZeneca

Attenuon

AVEO Pharmaceuticals

Barr Laboratories

Bayer Healthcare

Baylor College of Medicine

Biogen Idec

BioInvent

Bionovo

Biotech Research & Innovation Centre [Copenhagen, Denmark]

Biotest

BioWa

BiPar Sciences (a subsidiary of Sanofi)

Boehringer Ingelheim

Bristol-Myers Squibb (BMS)

British Biotech

BTG

Canadian National Research Council

Cancer Research Technology

Cancer Research UK

Cancer Science Institute of Singapore (CSI Singapore)

Celanese

Celgene

Cell Therapeutics

Centres for Disease Control and Prevention (US)

Centocor Ortho Biotech

Centocor Research & Development

Cephalon

Cetus Corporation

China's State Food and Drug Administration

Chiron

Choongwae

Cipla

Clavis Pharma

Cleveland Clinic

Columbia University

Compugen

Concordia Pharmaceuticals

Constellation Pharmaceuticals

Cougar Biotechnology

Crinos

CTI Technologies

CuraGen

CureVac

Cyclacel Pharmaceuticals

CyDex

Cylene

Cytogen

Cytokinetics

CytRx

Daiichi Sankyo

Dako

Dana Farber Cancer Institute

Dendreon

Dr. Reddy's Laboratories

Eisai

Elan

Elara Pharmaceuticals

Eleison Pharmaceuticals

Eli Lilly

Endocyte

EntreMed

EpiTherapeutics

Epizyme

European Medicines Agency (EMEA/EMA)

European Molecular Biology Laboratory (EMBL)

EUSA Pharma (formerly Cytogen)

Exelixis

Facet Biotech

Food and Drug Administration (US FDA)

Fresenius Kabi

Genentech (now part of Roche)

Generex Biotechnology

Genmab

Genta

Genzyme

Geron

GlaxoSmithKline (GSK)

Gloucester Pharmaceuticals

GlycoGenesys

GlycoMimetics

GPC Biotech

Greenwich Therapeutics

GTC Biotherapeutics

Handok

Harvard University

Hospira

Human Genome Sciences

IkerChem

ILEX Oncology

ImClone Systems (a subsidiary of Eli Lilly)

Immune System Therapeutics

ImmunoGen

Incyte

Infinity Pharmaceuticals

Innate Pharma

Intas Biopharmaceuticals

Intellikine

International Cancer Genome Consortium

International Myeloma Working Group

Introgen Therapeutics

Isis Pharmaceuticals

Italfarmaco

Janssen-Cilag

Johnson & Johnson (J&J)

Kadmon Pharmaceuticals

Kaken

Karyopharm Therapeutics

Keryx Biopharmaceuticals

Keyaku Zentaris

Kosan Biosciences

KTB Tumorforschungs

Kyowa Hakko Kirin

Les Laboratoires Servier

Leuchemix

Leukaemia and Lymphoma Society

Ligand

Lipomed

Lonza

Mannkind

Marlborough Research and Development

Marshall Edwards

MD Anderson Cancer Center

MedImmune

Medivation

Merck & Co.

Merck KGaA

Merck Serono (part of Merck KGaA)

MethylGene

Micromet

Millennium Pharmaceuticals (now part of Takeda)

MorphoSys

Mount Sinai Medical Center [US]

Multiple Myeloma Research Consortium

Multiple Myeloma Research Foundation

Mylan Pharmaceuticals

Natco Pharma

National Cancer Institute (NCI) [US]

National Cancer Institute (US)

National Health Service (NHS) [UK]

National Institute for Clinical Excellence (NICE) [UK]

National University Cancer Institute Singapore (NCIS)

NCIC Clinical Trials Group

Nektar Therapeutics

Nereus

Nerviano Medical Sciences

Nippon Shinyaku

Novartis

Novo Nordisk

Novogen

Ohio State University

OncoGenex Pharmaceuticals

Onconova

Oncova

Ono Pharmaceuticals

Onyx Pharmaceuticals

Ortho Biotech

OSI Pharmaceuticals

Otsuka

Oxford University

Par Pharmaceutical

PDL BioPharma

Pfizer

PharmaCenter Basel

Pharmaceutical Research and Manufacturers of America (PhRMA) [US]

Pharmacia

Pharmacopeia

Pharmacyclics

PharmaMar

Pharmion

Pierre Fabre Pharmaceuticals

Pipex

Piramal Life Sciences

PIramed

PolaRx Biopharmaceuticals

Poniard Pharmaceuticals

Proacta

Progenra

Prospect Therapeutics

Protein Design

Proteolix

R&R

Radient Pharmaceuticals

Regeneron

Rigel

Roche

Rockefeller University

Roxane Laboratories

S*BIO

Salk Institute for Biological Studies

Sandoz (part of Novartis)

Sanofi (sanofi-aventis)

Scancell

Schering-Plough

Scripps Institution of Oceanography

Seattle Genetics

Semafore

Senesco

Shire

Sigma-Tau

Signal Pharmaceuticals

Sirton

Sloan-Kettering Institute

Spectrum Pharmaceuticals

Stada Arzneimittel

Sun Pharmaceuticals

Sunesis

Syndax Pharmaceuticals

Synta Pharmaceuticals

Taiho Pharma

Takeda

Tapestry Pharmaceuticals

TargeGen

Telik

Teva Pharmaceutical Industries

Texas A&M University

The NCIC Clinical Trials Group (Canada)

Threshold Pharmaceuticals

TMRC

Toko

TopoTarget

Tragara

Tufts University

University of Basel PharmaCenter (PharmaCenter Basel)

University of Cambridge

University of Kentucky College of Pharmacy

University of Michigan

University of San Diego

US National Cancer Institute

US National Comprehensive Cancer Network

Vernalis

VioQuest

Wayne State University

WILEX

World Health Organization (WHO)

Wyeth

Xencor

XOMA

XTL Biopharmaceuticals

Yakult Honsha

Yeda Research and Development Company

YM Biosciences

Zelos

Zeltia

Zenyaku Kogyo

Zeria

Ziopharm

To order this report:Biological_Therapy Industry: Small-Molecule Targeted Cancer Therapies: World Market 2013-2023

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2016 Silicon Valley. The 19th Cloud Expo and 6th @ThingsExpo will take place on November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Interne...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
We’ve been doing it for years, decades for some. How many websites have you created accounts on? Your bank, your credit card companies, social media sites, hotels and travel sites, online shopping sites, and that’s just the start. We do it often without even thinking about it, quickly entering our personal information, our data, in a plethora of systems. Sometimes we’re not even aware of the information we are providing. It could be very personal information (think of the security questions you ...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
According to Forrester Research, every business will become either a digital predator or digital prey by 2020. To avoid demise, organizations must rapidly create new sources of value in their end-to-end customer experiences. True digital predators also must break down information and process silos and extend digital transformation initiatives to empower employees with the digital resources needed to win, serve, and retain customers.
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, will discuss how VPaaS enables you to move fast, creating scalable video experiences that reach your...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
Businesses are struggling to manage the information flow and interactions between all of these new devices and things jumping on their network, and the apps and IT systems they control. The data businesses gather is only helpful if they can do something with it. In his session at @ThingsExpo, Chris Witeck, Principal Technology Strategist at Citrix, will discuss how different the impact of IoT will be for large businesses, expanding how IoT will allow large organizations to make their legacy ap...
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...